Live·Open questions in longevity research
All news
Longevity researchTherapeuticsBiotech funding

Investor Karl Pfleger proposes two mouse experiments to guide aging research funding: test popular drugs under an optimal diet and compare how lifespan gains increase as therapies that slow aging through metabolism or repair damage are added

13 November 2026· 261113009

Investor Karl Pfleger proposes two mouse experiments to guide aging research funding: test popular drugs under an optimal diet and compare how lifespan gains increase as therapies that slow aging through metabolism or repair damage are added

On November 11, during a debate between Pfleger and aging researcher João Pedro de Magalhães, a reader asked which combination of therapies would double mouse lifespan. In his reply, Pfleger described two experiments he would fund.

The debate over how to measure the success of therapies has been ongoing since August. Pfleger considers lifespan studies of individual therapies a waste of resources: their results cannot establish whether a therapy would be useful in a future combination of dozens of treatments. He made this argument in a September 24 essay. On November 11, de Magalhães agreed that combinations were needed, but countered:

“I agree that lifespan is an imperfect metric, but it remains the most reliable and objective way to evaluate potential interventions against aging.”

The first experiment would test popular therapies, starting with GLP-1 drugs (used to treat diabetes and obesity) and rapamycin (which extends mouse lifespan). For each combination of mouse strain and sex, researchers would identify the optimal diet, defined as the daily calorie intake that produces the longest lifespan, and feed it to both treated and control mice. According to a 2010 PNAS paper, many standard laboratory control rodents are overfed, sedentary, and obese, so treatments that help them may not help active people of normal weight.

With an optimal diet, overeating would no longer affect the comparison, and Pfleger expects the benefits of both drugs to become negligible. The 92 days of additional lifespan in female mice given semaglutide (a GLP-1 drug) in a study published in Nature cannot be separated from the effect of diet: the mice ate 24% less, and untreated mice eating the same amount were not followed for their full lifespan.

The second experiment would refine the LEV Foundation experiments with combinations of therapies. Therapies would be divided into two categories: those that slow aging through metabolism (such as rapamycin) and those that repair specific forms of damage, such as a senolytic (which removes senescent cells). Within each category, researchers would measure the lifespan gains from one therapy, two therapies, three therapies, and so on.

Pfleger suspects that one or two therapies that slow aging would have a greater effect than one or two damage-repair therapies. Each additional therapy that slows aging would then add less, whereas the gains from damage-repair therapies would increase progressively faster, perhaps starting near zero when only a few therapies are used. His essay illustrates this reasoning with an imaginary boat: its hull leaks and weeds become tangled around its propeller, and either problem will eventually cause the boat to fail. Patching the hull or clearing the propeller alone does not extend its useful life, but doing both extends it severalfold. The essay argues that aging likewise involves several distinct forms of damage, all of which would need repair.

Pfleger concludes that too much funding currently goes to GLP-1 drugs and other therapies that alter metabolism, provided his predictions are correct and the field aims to treat aging processes shared by all people, including those with a normal body mass index of around 22, and to develop therapies for future combinations.

He estimates that the first experiment would cost a six-figure sum and an initial attempt at the second would cost a seven-figure sum. He suspects that mouse lifespan has yet to be doubled, but that the goal is within reach. His guess is that it would require 10–20 therapies, mostly damage-repair therapies, with the dose and starting time tailored to each mouse. He estimates that a small-scale program modeled on the Apollo moon program would cost 20–50 million dollars and would probably double mouse lifespan within 5–10 years.

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#mouse-lifespan#combination-therapies#damage-repair#rapamycin#glp-1#optimal-diet